Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: To find a complete list of Publications, please see listing here.
Found 151 results
“Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials.”, Biol Blood Marrow Transplant, vol. 22, no. 6, pp. 1133-1137, 2016.
, “Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902 Data.”, Biol Blood Marrow Transplant, vol. 22, no. 11, pp. 2077-2083, 2016.
, “A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.”, Blood, vol. 128, no. 21, pp. 2561-2567, 2016.
, “US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.”, Blood Adv, vol. 1, no. 3, pp. 250-259, 2016.
, “Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.”, J Antimicrob Chemother, vol. 71, no. 8, pp. 2234-40, 2016.
, “Blood and marrow transplant clinical trials network state of the Science Symposium 2014.”, Biol Blood Marrow Transplant, vol. 21, no. 2, pp. 202-24, 2015.
, “Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.”, Biol Blood Marrow Transplant, vol. 21, no. 6, pp. 1029-36, 2015.
, “Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial.”, Biol Blood Marrow Transplant, vol. 21, no. 10, pp. 1815-22, 2015.
, “Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.”, Lancet Haematol, vol. 2, no. 9, pp. e367-75, 2015.
, “Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo”, J Clin Oncol, vol. 33, no. 35, pp. 4167-75, 2015.
, “A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.”, Lancet Haematol, vol. 2, no. 1, pp. e21-9, 2015.
, “Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).”, Biol Blood Marrow Transplant, vol. 21, no. 1, pp. 4-7, 2015.
, “A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.”, Biol Blood Marrow Transplant, vol. 21, no. 4, pp. 761-7, 2015.
, “Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007.”, Biol Blood Marrow Transplant, vol. 20, no. 2, pp. 149-53, 2014.
, “Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer.”, J Comp Eff Res, vol. 3, no. 2, pp. 135-44, 2014.
, “Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1530-6, 2014.
, “Health-related quality of life of bone marrow versus peripheral blood stem cell donors: a prespecified subgroup analysis from a phase III RCT-BMTCTN protocol 0201.”, Biol Blood Marrow Transplant, vol. 20, no. 1, pp. 118-27, 2014.
, “Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.”, J Clin Oncol, vol. 32, no. 22, pp. 2365-72, 2014.
, “Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1485-92, 2014.
, “Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and M”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1566-72, 2014.
, “One-unit versus two-unit cord-blood transplantation for hematologic cancers.”, N Engl J Med, vol. 371, no. 18, pp. 1685-94, 2014.
, “Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.”, Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.
, “Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne”, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
, “Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.”, Blood, vol. 124, no. 8, pp. 1372-7, 2014.
, “Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).”, Curr Hematol Malig Rep, vol. 9, no. 1, pp. 57-65, 2014.
,